WEBULL
WebtradeDownload

CVS Health (CVS) Puts Biosimilars At The Center Of Drug Coverage

Simply Wall St · 2d ago
  • CVS Health (NYSE:CVS) unit CVS Caremark is accelerating biosimilar use to improve affordability and access for US patients.
  • The pharmacy benefit manager is the first large PBM to replace certain branded biologic drugs with lower cost biosimilars across its formularies.
  • CVS Caremark is broadening biosimilar coverage across multiple therapeutic areas, affecting treatment options for a wide range of conditions.
  • The biosimilar push at CVS Caremark is important, but there are other aspects of CVS Health that investors should weigh. Take a look at 1 warning sign we have identified for CVS Health.

For readers interested in how this broader shift toward lower cost drug options connects with healthcare technology, the wider trend around treatment access and pricing is worth tracking through 36 healthcare AI stocks.

NYSE:CVS Earnings & Revenue Growth as at Nov 2026
NYSE:CVS Earnings & Revenue Growth as at Nov 2026

CVS Health runs a large US pharmacy benefits and care delivery platform, so any shift in its drug coverage decisions can influence prescribing habits, patient access, and how manufacturers position branded biologics against biosimilar competitors.

5 things going right for CVS Health that this headline doesn't cover.

CVS Health’s biosimilar push tests the “lowest net cost” promise

The CVS Health Narrative hangs on Aetna underwriting discipline, Caremark contract quality, and tech driven savings turning healthcare demand into steadier earnings. This biosimilar move plugs straight into that storyline by stressing lower net drug costs and more predictable pharmacy economics.

"The shift in pharmacy and PBM economics toward lowest net cost and cost based reimbursement, including CVS CostVantage and the focus on achieving a fair margin on every script..."

See how the full story points towards a $114 fair value for CVS Health.

By leaning into biosimilars, CVS Caremark is effectively stress testing that “fair margin on every script” idea in one of the toughest arenas, high cost biologics where AbbVie and Janssen have relied on brand strength. For the Narrative, this looks like progress on the pharmacy side of the equation rather than a change in direction.

The tougher question is execution. CVS Health already faces membership and 340B headwinds in its PBM unit, and a faster shift to biosimilars could compress branded rebate economics before volume patterns settle. That trade off is what differentiates CVS from rivals such as UnitedHealth’s OptumRx or Cigna’s Express Scripts in the push toward lowest net cost models.

News like this only really makes sense once you have a clear view of where CVS Health wants its earnings mix to go. That is exactly what a well defined Narrative gives you.

The CVS Health detail hiding in plain sight that most holders never check

Analysts already map out where they think CVS Health ends up a few years from now, and those paths often point somewhere current headlines do not hint at. See where analysts expect CVS Health to be in a few years.